Clinical trial · Observational
PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objectives of this pilot feasibility study, which is on the use of 68-Ga PSMA PET imaging of salivary gland tumours, are * to determine the proportion of patients with high PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancer; and * to determine if in vitro PSMA expression correlates to PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers. The hypotheses of this study are that there is high PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers; and that in vitro PSMA expression correlates to PSMA-ligand uptake on Ga-68 PSMA imaging.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rare Malignant Neoplasm | Rare Childhood Malignant Neoplasm | ALIAS | 0.90 |
| Salivary Gland Tumor | Salivary Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68-Ga PSMA PET scan | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 68-Ga PSMA PET scan
- description
- 68-Ga PSMA PET scan
- interventionNames
- Diagnostic Test: 68-Ga PSMA PET scan
Primary outcomes (1)
- measure
- The proportion of patients with high PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancer.
- timeFrame
- Through study completion, to June 2024.
- description
- The proportion of patients with PSMA-ligand uptake greater than liver uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancer.
Secondary outcomes (1)
- measure
- Correlation between in vitro PSMA expression and PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Locally advanced, metastatic or locally recurrent salivary gland cancers OR rare cancers (Examples of rare cancers: thyroid ca, cholangio ca, pancreatic ca, gall bladder ca, sarcoma) * Sample of biopsied tissue available for analysis * Histologically confirmed diagnoses * Above 21 years of age * Able to provide informed consent Exclusion Criteria: * Those who do not meet above inclusion criteria * Diagnosis of haematological malignancies * Patients with more than one cancer diagnosis * Contraindication to 68Ga-PSMA PET/CT * E.g.: pregnant patients, breast feeding patients, renal impairment, liver impairment, allergy to components of the test * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule * Ongoing participation in any other clinical trial
References
Publications (0)
Data not yet available